Literature DB >> 20828615

Anti-viral opportunities during transcriptional activation of latent HIV in the host chromatin.

Shiraz Mujtaba1, Ming-Ming Zhou.   

Abstract

Human immunodeficiency virus (HIV) when integrated into a host chromosome exists in a transcriptionally inactive but replication-competent state. Such latent infection represents a major challenge to HIV eradication efforts because a permanent virus reservoir resided in the infected cell is able to spike the viral load on immune suppression or during interruption of highly active anti-retroviral therapy. Understanding the molecular mechanisms that control HIV proviral latency and its reactivation could provide new perspectives on host factors as therapeutic targets for abolishing cellular reservoirs of dormant HIV. Although the control of HIV latency is multifactorial, chromatin structure and the chromatin-associated transcriptional machinery are known to be important factors. For instance, transcription initiation of the HIV provirus involves a complex molecular interplay between chromatin-associated proteins and the virus-encoded trans-activator, Tat. The first part of this review discusses our current understanding of the elements involved in HIV transcriptional activation and viral mRNA elongation, mainly post-translational modifications of HIV Tat and its interactions with host chromatin-modifying enzymes and chromatin-remodeling complexes. The second part highlights new experimental therapeutic approaches aimed at administrating activators of HIV gene expression to reduce or eliminate the pool of latently HIV-infected cells. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20828615      PMCID: PMC3580173          DOI: 10.1016/j.ymeth.2010.09.001

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  68 in total

1.  Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter.

Authors:  Marina Lusic; Alessandro Marcello; Anna Cereseto; Mauro Giacca
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

2.  Acetylation of the HIV-1 Tat protein: an in vitro study.

Authors:  Wilma Dormeyer; Alexander Dorr; Melanie Ott; Martina Schnölzer
Journal:  Anal Bioanal Chem       Date:  2003-07-09       Impact factor: 4.142

3.  Methods and tips for the purification of human histone methyltransferases.

Authors:  Kenichi Nishioka; Danny Reinberg
Journal:  Methods       Date:  2003-09       Impact factor: 3.608

4.  HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription.

Authors:  Nanhai He; Min Liu; Joanne Hsu; Yuhua Xue; Seemay Chou; Alma Burlingame; Nevan J Krogan; Tom Alber; Qiang Zhou
Journal:  Mol Cell       Date:  2010-05-14       Impact factor: 17.970

5.  The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.

Authors:  C Van Lint; S Emiliani; E Verdin
Journal:  Gene Expr       Date:  1996

6.  Interaction of HIV gp120 and anti-CD4 antibodies with the CD4 molecule on human CD4+ T cells inhibits the binding activity of NF-AT, NF-kappa B and AP-1, three nuclear factors regulating interleukin-2 gene enhancer activity.

Authors:  N Jabado; F Le Deist; A Fisher; C Hivroz
Journal:  Eur J Immunol       Date:  1994-11       Impact factor: 5.532

7.  Crystal structure of HIV-1 Tat complexed with human P-TEFb.

Authors:  Tahir H Tahirov; Nigar D Babayeva; Katayoun Varzavand; Jeffrey J Cooper; Stanley C Sedore; David H Price
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

8.  Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation.

Authors:  Katrin Kaehlcke; Alexander Dorr; Claudia Hetzer-Egger; Veronique Kiermer; Peter Henklein; Martina Schnoelzer; Erwann Loret; Philip A Cole; Eric Verdin; Melanie Ott
Journal:  Mol Cell       Date:  2003-07       Impact factor: 17.970

9.  Selection and characterization of small molecules that bind the HIV-1 frameshift site RNA.

Authors:  Ryan J Marcheschi; Kathryn D Mouzakis; Samuel E Butcher
Journal:  ACS Chem Biol       Date:  2009-10-16       Impact factor: 5.100

Review 10.  Latency: the hidden HIV-1 challenge.

Authors:  Alessandro Marcello
Journal:  Retrovirology       Date:  2006-01-16       Impact factor: 4.602

View more
  6 in total

Review 1.  Protein lysine acetylation by p300/CBP.

Authors:  Beverley M Dancy; Philip A Cole
Journal:  Chem Rev       Date:  2015-01-16       Impact factor: 60.622

2.  Live-cell studies of p300/CBP histone acetyltransferase activity and inhibition.

Authors:  Beverley M Dancy; Nicholas T Crump; Daniel J Peterson; Chandrani Mukherjee; Erin M Bowers; Young-Hoon Ahn; Minoru Yoshida; Jin Zhang; Louis C Mahadevan; David J Meyers; Jef D Boeke; Philip A Cole
Journal:  Chembiochem       Date:  2012-09-07       Impact factor: 3.164

3.  Anthrax SET protein: a potential virulence determinant that epigenetically represses NF-κB activation in infected macrophages.

Authors:  Shiraz Mujtaba; Benjamin Y Winer; Anbalagan Jaganathan; Jigneshkumar Patel; Miriam Sgobba; Raymond Schuch; Yogesh K Gupta; Shozeb Haider; Rong Wang; Vincent A Fischetti
Journal:  J Biol Chem       Date:  2013-05-29       Impact factor: 5.157

4.  The biology of lysine acetylation integrates transcriptional programming and metabolism.

Authors:  Jigneshkumar Patel; Ravi R Pathak; Shiraz Mujtaba
Journal:  Nutr Metab (Lond)       Date:  2011-03-03       Impact factor: 4.169

Review 5.  Dichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer Cells.

Authors:  Ravi Pathak; Marc Philizaire; Shiraz Mujtaba
Journal:  Cancers (Basel)       Date:  2015-08-19       Impact factor: 6.639

Review 6.  The Biological Significance of Targeting Acetylation-Mediated Gene Regulation for Designing New Mechanistic Tools and Potential Therapeutics.

Authors:  Chenise O'Garro; Loveth Igbineweka; Zonaira Ali; Mihaly Mezei; Shiraz Mujtaba
Journal:  Biomolecules       Date:  2021-03-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.